Should you buy iRadimed (IRMD)?
Updated
iRadimed is a high-quality small-cap franchise with a wide economic moat, best-in-class margins, and a near-perfect financial health score, but the shares trade at a forward earnings multiple of 38.6x — a valuation that leaves little margin of safety — and an elevated options skew signals meaningful near-term uncertainty.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
The business carries a wide economic moat, operating margins of 27%, return on equity of 25%, and a perfect 9-out-of-9 financial health score — a combination of profitability, returns, and financial strength that ranks among the best in its peer group. Quality breakdown | Operating margins stay above 24% and return on equity remains above 20% over the next four reported quarters. | →Stable |
| CounterSmall-cap franchises with wide moats can see competitive inroads if a larger incumbent dedicates resources to the segment; the financial health scores are backwards-looking and may not reflect an evolving competitive landscape. | ||
The put-to-call ratio stands at 4.0 and implied volatility is at 72%, levels that suggest the options market is pricing in significant near-term uncertainty despite the solid underlying fundamentals. Risk breakdown | The put-to-call ratio falls below 1.5 and implied volatility compresses below 40% as near-term event risk resolves. | →Stable |
| CounterElevated put-to-call ratios in small-cap names with limited analyst coverage often reflect hedging by concentrated holders rather than broad bearish conviction; the signal may overstate the actual fundamental risk. | ||
The company posted three beats and one in-line result across the last four quarters, with an average positive surprise of approximately 9.6%, suggesting the business is consistently under-promising and over-delivering on quarterly expectations. Earnings | The beat-or-in-line streak extends to six consecutive quarters and average surprise remains above 5% per period. | →Stable |
| CounterAverages can mask individual quarter volatility; the one in-line quarter within the streak shows the upside surprise is not perfectly consistent, and even a modest earnings miss at a 38x multiple would likely produce a sharp price reaction. | ||
The business carries a wide economic moat, operating margins of 27%, return on equity of 25%, and a perfect 9-out-of-9 financial health score — a combination of profitability, returns, and financial strength that ranks among the best in its peer group.
→Stable- Expectation
- Operating margins stay above 24% and return on equity remains above 20% over the next four reported quarters.
CounterSmall-cap franchises with wide moats can see competitive inroads if a larger incumbent dedicates resources to the segment; the financial health scores are backwards-looking and may not reflect an evolving competitive landscape.
The put-to-call ratio stands at 4.0 and implied volatility is at 72%, levels that suggest the options market is pricing in significant near-term uncertainty despite the solid underlying fundamentals.
→Stable- Expectation
- The put-to-call ratio falls below 1.5 and implied volatility compresses below 40% as near-term event risk resolves.
CounterElevated put-to-call ratios in small-cap names with limited analyst coverage often reflect hedging by concentrated holders rather than broad bearish conviction; the signal may overstate the actual fundamental risk.
The company posted three beats and one in-line result across the last four quarters, with an average positive surprise of approximately 9.6%, suggesting the business is consistently under-promising and over-delivering on quarterly expectations.
→Stable- Expectation
- The beat-or-in-line streak extends to six consecutive quarters and average surprise remains above 5% per period.
CounterAverages can mask individual quarter volatility; the one in-line quarter within the streak shows the upside surprise is not perfectly consistent, and even a modest earnings miss at a 38x multiple would likely produce a sharp price reaction.
▸ Show 1 more pillar▾ Show fewer
At a forward price-to-earnings multiple of 38.6x and a price-to-growth ratio of 1.74, the shares are priced expensively relative to the growth profile, leaving the setup dependent on continued execution with no room for disappointment.
→Stable- Expectation
- The forward P/E compresses below 28x through earnings growth rather than price decline, demonstrating the valuation is being grown into.
CounterHigh-quality franchises with wide economic moats and consistent double-digit earnings beats can sustain premium multiples for extended periods; 38x may simply reflect appropriate pricing for the business quality on offer.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The business carries a wide economic moat, operating margins of 27%, return on equity of 25%, and a perfect 9-out-of-9 financial health score — a combination of profitability, returns, and financial strength that ranks among the best in its peer group.
Trip ifOperating margin falls below 20% for 2 consecutive reported quarters.
- P2The company posted three beats and one in-line result across the last four quarters, with an average positive surprise of approximately 9.6%, suggesting the business is consistently under-promising and over-delivering on quarterly expectations.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, breaking the beat-or-in-line streak.
- P3At a forward price-to-earnings multiple of 38.6x and a price-to-growth ratio of 1.74, the shares are priced expensively relative to the growth profile, leaving the setup dependent on continued execution with no room for disappointment.
Trip ifForward P/E compresses below 25x as earnings estimates rise more than 30% from current levels.
- P4The put-to-call ratio stands at 4.0 and implied volatility is at 72%, levels that suggest the options market is pricing in significant near-term uncertainty despite the solid underlying fundamentals.
Trip ifPut-to-call ratio falls below 1.5 for 4 or more consecutive weeks.
How the engine reached this verdict
TrendMatrix's engine output for iRadimed Corporation (IRMD) is SELL_IF_HOLDING with medium conviction, score 5.4/10 at $95.42. The F-path SELL output reflects an overall score of 5.4 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 0.74 is supplementary context, not the trigger.
The engine's exit framework anchors to a tactical sell band near $95.42, with structural invalidation at $88.46. The asymmetric R:R against a reversal hypothesis is 0.80 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bull side: Strong earnings beat streak (3/4); High-quality business; Wide economic moat. On the bear side: Thin upside margin: 5.5%; Expensive valuation. Active engine warnings: V9 Gate Failed: ASYMMETRY:0.7<1.5@spot.
The dominant failed gate is reward-to-risk at 0.7 vs threshold 1.5. SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.2>=5.5.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates IRMD — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (3/4)
- ▸High-quality business
- ▸Wide economic moat
Bear case
- ▸Thin upside margin: 5.5%
- ▸Expensive valuation